| SYM | Name |
|---|---|
![]() | SPAC/IPO |
![]() | LOI |
![]() | Vereinbarung |
![]() | Wahl |
![]() | Fusion |
![]() | IPO |
![]() | Abwicklung |


SPAC Events and Deal Milestones
Everything at a Glance!
Stay informed about the most important events in the SPAC and IPO market. From upcoming public offerings to merger votes, we provide a central overview of all key dates.

Events
| details_shortcode_en | Year | Month | Status | Industry | sec_cik_company | sec_cik_spac | name_company | name_spac | ticker_company | ticker_spac | ticker_stockdio | ticker_spac_stockdio | stock_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biotechnology
Initial Public Offering / IPO
IPO:
Nov 13, 2026 ![]() Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. About WINDWARD BIO GROUP AG: Windward Bio Group AG is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis.
The company estimates that these diseases represent a combined peak market opportunity of $60 billion for biologic therapies. Although more than 100 million people across the United States, the EU5 (France, Germany, Italy, Spain and the United Kingdom) and Japan are affected, Windward Bio Group AG believes that most patients eligible for biologic treatment remain untreated. More than 8 million people in these regions are estimated to be eligible for biologics.
Windward Bio Group AG’s product candidates are being developed to address this unmet need, potentially extending treatment to a broader patient population while improving efficacy, dosing convenience and treatment adherence. | 2026 | 11 / November | ![]() | Biotechnology | 2.145.089 | WINDWARD BIO GROUP AG | WWB | WWB | 4.675 | ||||
Health
Initial Public Offering / IPO
IPO:
Nov 13, 2026 ![]() Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. About vVARDIS Holding AG: Drawing on extensive industry experience, market understanding and clinical evidence, Curodont® is a first-in-category healthcare platform: the first clinically validated treatment for early-stage cavities designed to preserve natural tooth structure and restore enamel crystal density throughout the lesion, in a process similar to natural tooth formation. This proprietary peptide-enabled technology offers an early therapeutic approach to tooth decay—the world’s most prevalent non-communicable disease—and addresses a substantial global healthcare need where effective medical options for early intervention have historically been limited. | 2026 | 11 / November | ![]() | Health | 1.907.709 | vVARDIS Holding AG | VVVV | VVVV | 4.674 | ||||
SPAC
Unit Split
Unit Split:
Nov 13, 2026 ![]() Industry: BLANK CHECKS Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. News: Nov 10, 2026 5:33 PM ET
6/10
Nov 10, 2026 Live Oak Acquisition Corp. VI Unit SeparationLive Oak Acquisition Corp. VI announces separate trading of Class A ordinary shares and warrants starting November 13,…
7/10
Sep 24, 2026 Live Oak Acquisition Corp. VI Completes $230M IPOLive Oak Acquisition Corp. VI closes $230 million initial public offering on Nasdaq under ticker LOVIU. Read more… About Live Oak Acquisition Corp. VI: Live Oak Acquisition Corp. VI is a blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We may pursue an initial business combination in any business, industry, sector, or geographic location. | 2026 | 11 / November | ![]() | SPAC | 2.115.191 | Live Oak Acquisition Corp. VI | LOVI | LOVI | 4.611 | ||||
Biotechnology
Merger Vote
Merger Vote:
Nov 11, 2026 ![]() Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS Market Cap.: 38.13 m. Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. News: Sep 18, 2024 5:41 PM ET
4/10
Sep 18, 2024 MCAG Receives Nasdaq Deficiency Notice for Late FilingsMountain Crest Acquisition Corp. V (MCAG) received a Nasdaq deficiency notice for delayed Q1 & Q2 10-Q filings…
7/10
Aug 30, 2024 CUBEBIO Partners with Mountain Crest V for Nasdaq ListingCUBEBIO and Mountain Crest V announce definitive business combination agreement, aiming to list CUBEBIO's early-stage cancer diagnostic technology…
3/10
Jul 24, 2024 Mountain Crest Acquisition Corp. V Receives Nasdaq Deficiency NoticeMountain Crest Acquisition Corp. V (MCAG) announced it received a deficiency notification from Nasdaq due to delayed filing… About CUBEBIO: CUBEBIO is an in-vitro diagnostic company that has developed a technology that can distinguish the presence of cancer in the body at an early stage by analyzing the concentration of specific metabolites in urine using urine that can be easily collected, with a focus on increasing the accessibility of cancer screening. CUBEBIO holds 37 Korean patents related to cancer diagnosis, based on which it has developed CEED-PG/PGS in addition to the pancreatic cancer diagnostic kit CEED-NOVUS-P and the multi-cancer detection kit CEED-NOVUS. Recently, through a KRW 20 billion or approximately $14.5 million contract with Taiwan Biotech Co., Ltd. to supply cancer screening products, CUBEBIO will exclusively supply its products to Taiwan, Vietnam, and Malaysia (the “Taiwan Biotech Contract”). CUBEBIO does not expect to generate revenues under the Taiwan Biotech Contract until CUBEBIO’s products are approved for sale in Taiwan, Vietnam, and Malaysia which may take up to 24 months or more. CUBEBIO is in the process of working on agreements to supply its cancer screening products in the United States and Japan. | 2026 | 11 / November | ![]() | Biotechnology | 1.859.035 | CUBEBIO | Mountain Crest Acquisition Corp. V | MCAG | MCAG | 1.115 | |||
SPAC
Unit Split
Unit Split:
Nov 10, 2026 ![]() Industry: BLANK CHECKS Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. News: Nov 09, 2026 6:10 AM ET
5/10
Nov 09, 2026 SPACCircle Announces Separate Trading of Shares and WarrantsSPACCircle Acquisition Corp. announces that Class A ordinary shares, warrants, and rights from its IPO will begin separate…
7/10
Oct 28, 2026 SPACCircle Acquisition Corp. Completes $100M IPOSPACCircle Acquisition Corp. closed its $100 million initial public offering on Nasdaq under the symbol SCQCU. Learn more… About SPACCircle Acquisition Corp.: SPACCircle Acquisition Corp. is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this prospectus as our initial business combination. We have not selected any specific target business and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any target business regarding any initial business combination with our company. | 2026 | 11 / November | ![]() | SPAC | 2.131.303 | SPACCircle Acquisition Corp. | SCQC | SCQC | 4.646 | ||||
News: Nov 10, 2026 5:11 PM ET | 2026 | 11 / November | ![]() | Crypto / Blockchain | 2.043.766 | Nature's Ledger Inc. | Globa Terra Acquisition Corp | GTER | GTERA | 3.557 | |||
SPAC
Unit Split
Unit Split:
Nov 09, 2026 ![]() Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. News: Nov 09, 2026 5:27 PM ET
5/10
Nov 09, 2026 Haymaker Acquisition V Announces Separate Trading of SharesHaymaker Acquisition Corp V announces that Class A ordinary shares and warrants from its units will trade separately…
7/10
Sep 22, 2026 Haymaker Acquisition Corp V Completes $287.5M IPOHaymaker Acquisition Corp V completes its $287.5 million initial public offering on the NYSE under the ticker symbol… About Haymaker Acquisition Corp V: Haymaker Acquisition Corp V is a blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this prospectus as our initial business combination. We have not selected any business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We may pursue an initial business combination in any business or industry. | 2026 | 11 / November | ![]() | SPAC | 2.111.838 | Haymaker Acquisition Corp V | HYAC | HYAC | 4.605 | ||||
SPAC
Unit Split
Unit Split:
Nov 06, 2026 ![]() Industry: BLANK CHECKS Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. News: Nov 05, 2026 5:44 PM ET
5/10
Nov 05, 2026 Leader's Advantage Acquisition Corp. Unit Separation Nov 2026Leader's Advantage Acquisition Corp. (NASDAQ: LEDRU) announces that Class A ordinary shares and warrants will trade separately starting…
4/10
Oct 30, 2026 Leader's Advantage Acquisition Corp. Closes Over-AllotmentLeader's Advantage Acquisition Corp. closes partial over-allotment option exercise, raising total gross proceeds to $156.5 million for its…
7/10
Sep 23, 2026 Leader's Advantage Acquisition Corp. Closes $150M IPOLeader's Advantage Acquisition Corp. announces the closing of its $150,000,000 initial public offering on Nasdaq under the ticker… About Leader's Advantage Acquisition Corp.: Leader’s Advantage Acquisition Corp. is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We may pursue an initial business combination in any business or industry. | 2026 | 11 / November | ![]() | SPAC | 2.109.823 | Leader's Advantage Acquisition Corp. | LEDR | LEDR | 4.610 | ||||
Robotics
Merger / DESPAC
Merger:
Nov 05, 2026 ![]() Industry: GENERAL INDUSTRIAL MACHINERY & EQUIPMENT, NEC Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. News: Nov 06, 2026 4:25 PM ET
8/10
Nov 06, 2026 Agility Robotics Completes Business Combination with CCXIAgility Robotics completes its business combination with Churchill Capital Corp XI and will trade on Nasdaq under the…
8/10
Nov 02, 2026 Churchill XI Shareholders Approve Agility Robotics MergerChurchill Capital Corp XI shareholders approved the business combination with Agility Robotics, raising $465 million to support humanoid…
8/10
Oct 30, 2026 Agility Robotics SPAC Merger Valued at $465M Capital RaiseAgility Robotics and Churchill Capital Corp XI announce $465 million expected capital raise and business combination closing date… About Agility Robotics, Inc.: Agility’s commercially deployed humanoids operate alongside teams in warehouses, manufacturing facilities and distribution centers – tackling physically demanding and repetitive tasks while enabling workers to focus on higher-value work. With industry-leading safety standards and years of proven deployment data, we’re pioneering a new era of automation that enhances human potential. To learn more, visit [www.agilityrobotics.com]. | 2026 | 11 / November | ![]() | Robotics | 2.074.973 | 2.074.973 | Agility Robotics, Inc. | Churchill Capital Corp XI | AGLT | CCXI | AGLT | CCXI | 3.919 |
Artificial Intelligence
Definitive AgreementDefinitive Agreement: Nov 05, 2026 ![]() Presentation: Nov 09, 2026 6:08 PM ET News: Nov 05, 2026 9:21 AM ET | 2026 | 11 / November | ![]() | Artificial Intelligence | 2.097.288 | Nemi Corp. | BHAV Acquisition Corp | NEMI | BHAV | BHAV | 4.155 |












